Form 4: Pulmonx Director Richard Ferrari Receives Significant Restricted Stock Unit Grant

Pulmonx Corporation's Director, Richard Ferrari, was granted 37,153 Restricted Stock Units, increasing his beneficial ownership to 95,024 shares.

Summary

• Richard Ferrari, a Director of Pulmonx Corporation (LUNG), was granted 37,153 shares of common stock in the form of Restricted Stock Units (RSUs).
• This RSU grant was made on June 2, 2025, at a price of $0 per share, which is typical for equity compensation awards.
• Following this transaction, Mr. Ferrari's total beneficial ownership in Pulmonx Corporation increased to 95,024 shares of common stock.
• The RSUs are set to vest on the earlier of (i) the one-year anniversary of the grant date (June 2, 2025, or the next business day if not a business day) or (ii) the date of the Annual Meeting of Stockholders for the year subsequent to the grant date.

Sentiment

Score: 6

Explanation: The document reports a routine RSU grant to a director, which is a positive for aligning management interests with shareholders but does not contain information that would significantly alter the company's financial outlook or operations. It's a standard compensation event.

Positives

• The grant of 37,153 Restricted Stock Units to Director Richard Ferrari aligns his interests with long-term shareholder value.
• The increase in Mr. Ferrari's beneficial ownership to 95,024 shares demonstrates continued commitment from a key director.

Risks

• This document, a Form 4, primarily reports an insider transaction and does not typically detail company-specific operational or financial risks.

Future Outlook

This Form 4 filing primarily reports a past transaction (an RSU grant) and its vesting conditions, rather than providing a broader future outlook or guidance for the company's operations or financial performance.

Industry Context

The grant of Restricted Stock Units (RSUs) to a director is a common form of executive and director compensation in the medical technology and healthcare industry, aiming to align leadership incentives with long-term shareholder value. This practice is consistent with compensation strategies observed across publicly traded companies, including those focused on innovative medical devices like Pulmonx.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a compensation mechanism for directors is a standard practice across the medical device and broader technology sectors, including companies like Medtronic, Intuitive Surgical, and Boston Scientific, which frequently use equity awards to incentivize long-term performance and retention.
• The vesting schedule, tied to either a one-year anniversary or the next annual stockholder meeting, is also a common structure for director equity grants, ensuring continued engagement and oversight.
• The specific number of units granted (37,153) would need to be benchmarked against the company's overall compensation philosophy, market capitalization, and peer group compensation data to assess if it is within typical industry ranges for a director of a company of Pulmonx's size and stage. Without that context, it appears to be a routine grant.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Richard Ferrari, a director of Pulmonx Corporation, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with long-term shareholder value. It also represents a form of equity dilution, though typically minor for individual grants of this size.
• Employees: No direct impact on general employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• Vesting of the 37,153 Restricted Stock Units on the earlier of June 2, 2026, or the date of the Annual Meeting of Stockholders for the year subsequent to the grant date.

Key Dates

Keywords

Pulmonx Corp, LUNG, Richard Ferrari, Restricted Stock Units, RSU Grant, Insider Transaction, SEC Form 4, Director Compensation, Equity Grant, Beneficial Ownership